IBA
RELATED CONTENT
November 12, 2009 – IBA (Ion Beam Applications S.A.) introduced a smaller, two-room, and lower-cost footprint for traditional Proton Therapy centers for cancer treatment, called the Proteus Nano, at the 51st Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Nov. 1–5, 2009, at McCormick Place West in Chicago, Ill.
November 12, 2009 
September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.
September 21, 2009
February 23, 2009 - An advance in the way protons are delivered at the University of Florida Proton Therapy Institute — called uniform scanning — reportedly enable physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs.
February 23, 2009
December 23, 2008 - The FDA cleared Ion Beam Applications’ (IBA) cyclotron-based integrated commercial proton therapy system with pencil beam scanning (PBS), a delivery method that allows for precise dose delivery by its proton therapy system.
December 23, 2008
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal Nozzle alpha that reportedly allows treatment planners and clinicians to expand capabilities in choosing the optimal treatment beam delivery mode for each patient.
July 24, 2007
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal ...
July 24, 2007